Gizele Cabral Costa 1 , Tadeu Lima Montagnoli 2 , Jaqueline Soares Da Silva 2 , Allan Kardec Nogueira de Alencar 2 , Luis Eduardo Reina Gamba 2 , Bryelle Eccard Oliveira Alves 1 , 2 , Marina Moraes Carvalho da Silva 2 , Margarete Manhães Trachez 2 , José Hamilton M do Nascimento 2 , 3 , Pedro Moreno Pimentel-Coelho 3 , Rosália Mendez-Otero 3 , Lidia Moreira Lima 2 , Eliezer J Barreiro 2 , Roberto Takashi Sudo 2 , Gisele Zapata-Sudo 1 , 2
17 August 2020
Diabetic obese patients are susceptible to the development of cardiovascular disease, including hypertension and cardiac dysfunction culminating in diabetic cardiomyopathy (DC), which represents a life-threatening health problem with increased rates of morbidity and mortality. The aim of the study is to characterize the effects of a new benzofuran N-acylhydrazone compound, LASSBio-2090, on metabolic and cardiovascular alterations in Zucker diabetic fatty (ZDF) rats presenting DC.
Male non-diabetic lean Zucker rats (ZL) and ZDF rats treated with vehicle (dimethylsulfoxide) or LASSBio-2090 were used in this study. Metabolic parameters, cardiovascular function, left ventricle histology and inflammatory protein expression were analyzed in the experimental groups.
LASSBio-2090 administration in ZDF rats reduced glucose levels to 85.0 ± 1.7 mg/dL ( p < 0.05). LASSBio-2090 also lowered the cholesterol and triglyceride levels from 177.8 ± 31.2 to 104.8 ± 5.3 mg/dL and from 123.0 ± 11.4 to 90.9 ± 4.8 mg/dL, respectively, in obese diabetic rats ( p < 0.05). LASSBio-2090 normalized plasma insulin, insulin sensitivity and endothelial function in aortas from diabetic animals ( p < 0.05). It also enhanced systolic and diastolic left-ventricular function and reverted myocardial remodeling by blocking the threefold elevation of TNF-α levels in hearts from ZDF rats.